Immix Biopharma, Inc.
NASDAQ:IMMX
Overview | Financials
| Company Name | Immix Biopharma, Inc. |
| Symbol | IMMX |
| Currency | USD |
| Price | 2.17 |
| Market Cap | 62,570,019 |
| Dividend Yield | 0% |
| 52-week-range | 1.26 - 3.2 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. |
| Website | https://www.immixbio.com |
An error occurred while fetching data.
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD



